Oruka Therapeutics (ORKA) & The Competition Financial Analysis

Oruka Therapeutics (NASDAQ:ORKA) is one of 35 publicly-traded companies in the “Diagnostic substances” industry, but how does it compare to its rivals? We will compare Oruka Therapeutics to related companies based on the strength of its dividends, analyst recommendations, institutional ownership, profitability, earnings, valuation and risk.

Valuation & Earnings

This table compares Oruka Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-5.03
Oruka Therapeutics Competitors	$625.67 million	$7.82 million	-37.91

Oruka Therapeutics’ rivals have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 47.3% of shares of all “Diagnostic substances” companies are owned by institutional investors. 30.9% of Oruka Therapeutics shares are owned by insiders. Comparatively, 12.7% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Oruka Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Oruka Therapeutics Competitors	-456.55%	-21.40%	-14.61%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Oruka Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	855	801	1339	23	2.18

Oruka Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 42.98%. As a group, “Diagnostic substances” companies have a potential upside of 34.10%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than its rivals.

Risk and Volatility

Oruka Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ rivals have a beta of 1.25, indicating that their average stock price is 25% more volatile than the S&P 500.

Summary

Oruka Therapeutics beats its rivals on 9 of the 13 factors compared.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.